BRD4 and cancer: The inhibitor of BRD4 has great promise for cancer therapy, it competes with acetylated residues to bind to the BRD4 bromodomain, thereby reducing RNA-PolII flux and blocking transcription of key oncogenes (Donato et al., 2017).